Find, compare & contact
Brolucizumab
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Brolucizumab API 1531589-13-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Brolucizumab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Brolucizumab
- Synonyms:
- brolucizumab-dbll
- Cas Number:
- 1531589-13-5
- DrugBank number:
- DB14864
- Unique Ingredient Identifier:
- XSZ53G39H5
General Description:
Brolucizumab, identified by CAS number 1531589-13-5, is a notable compound with significant therapeutic applications. Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019.
Indications:
This drug is primarily indicated for: Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Brolucizumab undergoes metabolic processing primarily in: Monoclonal antibodies are expected to undergo proteolysis to smaller peptides and amino acids. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Brolucizumab are crucial for its therapeutic efficacy: A 3mg dose of brolucizumab reaches a Cmax of 20.7ng/mL with a Tmax of 20.3h and an AUC of 2480ng\*h/mL. A 6mg dose of brolucizumab reaches a Cmax of 77.6ng/mL with a Tmax of 17.4h and an AUC of 9169ng\*h/mL. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Brolucizumab is an important consideration for its dosing schedule: The systemic half life of bolucizumab is 4.4±2.0 days. The elimination half life is 108h for a 3mg dose and 103h for a 6mg dose. This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Brolucizumab exhibits a strong affinity for binding with plasma proteins: Monoclonal antibodies are generally not protein bound in serum. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Brolucizumab from the body primarily occurs through: Data regarding the route of elimination is not readily available. Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Brolucizumab is distributed throughout the body with a volume of distribution of: Data regarding the volume of distribution is not readily available. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Brolucizumab is a critical factor in determining its safe and effective dosage: Data regarding the clearance of brolucizumab is not readily available. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Brolucizumab exerts its therapeutic effects through: Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which reduces proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature. It has a long duration of action as it is given monthly. Patients should be counselled regarding the risk of endophthalmitis, retinal detachment, and arterial thromboembolic events following administration of this medication. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Brolucizumab functions by: Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Brolucizumab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Categories:
Brolucizumab is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Angiogenesis Inhibitors, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineovascularisation Agents, Blood Proteins, EENT Drugs, Miscellaneous, Globulins, Immunoglobulins, Immunoproteins, Ocular Vascular Disorder Agents, Ophthalmologicals, Proteins, Sensory Organs, Serum Globulins, Vascular Endothelial Growth Factor Inhibitor. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Brolucizumab include:
- Molecular Weight: 26000.0
Brolucizumab is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
